These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 1743921)
21. Biodistribution and magnetic resonance imaging of cross-linked DTPA polysaccharides. Gibby WA; Billings J; Hall J; Ovitt TW Invest Radiol; 1990 Feb; 25(2):164-72. PubMed ID: 1690184 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and stability of caldiamide sodium in rats. Okazaki O; Kurata T; Yoshioka N; Hakusui H Arzneimittelforschung; 1996 Jan; 46(1):79-83. PubMed ID: 8821523 [TBL] [Abstract][Full Text] [Related]
23. Dy-EOB-DTPA: tolerance and pharmacokinetics in healthy volunteers and preliminary liver imaging in patients. Krause W; Mahler M; Hanke B; Milius W; Kaufmann J; Rogalla P; Hamm B Invest Radiol; 2001 Aug; 36(8):431-44. PubMed ID: 11500593 [TBL] [Abstract][Full Text] [Related]
24. Can gadolinium be safely given in renal failure? Weissleder R AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405 [No Abstract] [Full Text] [Related]
25. Mannan-coated liposome delivery of gadolinium-diethylenetriaminepentaacetic acid, a contrast agent for use in magnetic resonance imaging. Kunimasa J; Inui K; Hori R; Kawamura Y; Endo K Chem Pharm Bull (Tokyo); 1992 Sep; 40(9):2565-7. PubMed ID: 1446380 [TBL] [Abstract][Full Text] [Related]
26. Hydrated clearance of gadolinium-DTPA as a measurement of glomerular filtration rate. Choyke PL; Austin HA; Frank JA; Girton ME; Diggs RL; Dwyer AJ; Miller L; Nussenblatt R; McFarland H; Simon T Kidney Int; 1992 Jun; 41(6):1595-8. PubMed ID: 1501414 [TBL] [Abstract][Full Text] [Related]
27. A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism. Gale EM; Wey HY; Ramsay I; Yen YF; Sosnovik DE; Caravan P Radiology; 2018 Mar; 286(3):865-872. PubMed ID: 29117483 [TBL] [Abstract][Full Text] [Related]
28. Quantification of dechelation of gadopentetate dimeglumine in rats. Kasokat T; Urich K Arzneimittelforschung; 1992 Jun; 42(6):869-76. PubMed ID: 1418049 [TBL] [Abstract][Full Text] [Related]
29. Comparative pharmacokinetics of gadolinium DTPA and gadolinium chloride. Dean PB; Niemi P; Kivisaari L; Kormano M Invest Radiol; 1988 Sep; 23 Suppl 1():S258-60. PubMed ID: 3198357 [TBL] [Abstract][Full Text] [Related]
30. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Schuhmann-Giampieri G; Schmitt-Willich H; Press WR; Negishi C; Weinmann HJ; Speck U Radiology; 1992 Apr; 183(1):59-64. PubMed ID: 1549695 [TBL] [Abstract][Full Text] [Related]
31. A macromolecular contrast agent for magnetic resonance imaging. Effect of molecular weight on blood pharmacokinetics and enhancement patterns for polylysine-gadopentetate dimeglumine. Vexler VS; Clément O; Brasch RC Invest Radiol; 1994 Jun; 29 Suppl 2():S62-4. PubMed ID: 7928273 [No Abstract] [Full Text] [Related]
33. Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. Jia J; Puls D; Oswald S; Jedlitschky G; Kühn JP; Weitschies W; Hosten N; Siegmund W; Keiser M Invest Radiol; 2014 Feb; 49(2):78-86. PubMed ID: 24056116 [TBL] [Abstract][Full Text] [Related]
34. Iopentol in patients with chronic renal failure: its effects on renal function and its use as glomerular filtration rate parameter. Berg KJ; Kolmannskog F; Lillevold PE; Nordal KP; Ressem L; Rootwelt K; Svaland MG Scand J Clin Lab Invest; 1992 Feb; 52(1):27-33. PubMed ID: 1594886 [TBL] [Abstract][Full Text] [Related]
35. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging. Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653 [TBL] [Abstract][Full Text] [Related]
36. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent. Van Wagoner M; Worah D Invest Radiol; 1993 Mar; 28 Suppl 1():S44-8. PubMed ID: 8486503 [TBL] [Abstract][Full Text] [Related]
37. Yb-DTPA, a novel contrast agent in magnetic resonance imaging: application to rat kidney. Sarkar SK; Rycyna RE; Lenkinski RE; Solleveld HA; Kinter LB Magn Reson Med; 1991 Feb; 17(2):328-35. PubMed ID: 2062207 [TBL] [Abstract][Full Text] [Related]
38. Renal effects of gadopentetate dimeglumine in patients with normal and impaired renal function. Hoffmann U; Fischereder M; Reil A; Fischer M; Link J; Krämer BK Eur J Med Res; 2005 Apr; 10(4):149-54. PubMed ID: 15946910 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time. Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd-DTPA-enhanced MRI. Su MY; Wang Z; Roth GM; Lao X; Samoszuk MK; Nalcioglu O Magn Reson Med; 1996 Dec; 36(6):868-77. PubMed ID: 8946352 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]